Updated

In a test conducted with investment firm Citrini Research, Anthropic's unreleased Claude Duet failed to synthesize scorpion antivenom, a key proof-of-concept for AI-driven drug development, according to The Verge on October 22. Claude generated some promising starting points but nothing approaching an actual drug, with experts noting that Citrini's team readily admitted they lacked expertise in AI-applied biology before attempting the experiment. The failure underscores current limitations in AI-driven pharmaceutical discovery despite widespread industry optimism about the technology's transformative potential. The public disclosure of the trial failure is notable given the hype surrounding AI in drug development, offering a reality check on near-term capabilities. While AI remains valuable for accelerating certain stages of research, the results suggest the technology is not yet ready to independently design working pharmaceuticals.